GHK-Cu Human Trials (2026): What the Data Shows
[News · Research peptides]

GHK-Cu Human Trials (2026): What the Data Shows

NCT07437586 · NCT07888595 · FDA category list, May 2026 · Checked November 15, 2026

Published · By Ethen Amezquita

Short answer: As of November 15, 2026, the human evidence for GHK-Cu comes from small trials of creams and serums on the skin, not injections. Two trials registered in 2026 add to that: a placebo-controlled phase 2 test of a GHK-Cu gel on small skin wounds (NCT07437586, recruiting 60 healthy adults since February 2, 2026) and a single-group aging study using a serum of GHK-Cu and four other peptides (NCT07888595, posted October 22, 2026). FDA lists injectable GHK-Cu among compounding substances that may pose significant safety risks, and it put non-injectable GHK-Cu back under review on May 14, 2026. Injected GHK-Cu is a research peptide, not approved for human use.

GHK-Cu, often called copper peptide, sits in two worlds: skin care on one side and research vials on the other. That makes it easy to mix up the evidence for a cream with the evidence for an injection. We checked ClinicalTrials.gov, PubMed and FDA's compounding lists on November 15, 2026. Each piece of evidence below is labelled human, animal or lab.

What GHK-Cu is

GHK is a three-amino-acid peptide (glycine, histidine, lysine) found in the human body. It binds copper to form GHK-Cu, as described in a 2008 review. Most of what is claimed for it comes from lab and animal work on wound healing and skin. It is widely used in cosmetic products. Our GHK-Cu compound page notes that we could not find a published human half-life.

Trials registered in 2026

TrialWhat it testsStatus
NCT07437586 (CuHeal), sponsor Hudson Biotech, Peking University Shenzhen HospitalPhase 2, double-blind. Each of 60 healthy adults (estimated) gets two small punch-biopsy wounds on the upper arm; one is treated with GHK-Cu gel and the other with a matching gel without it, once a day for 14 days. Main result: days until the wound is fully covered by new skin. Scars are checked at 12 weeks.Recruiting. Started February 2, 2026; estimated primary completion February 14, 2027.
NCT07888595, sponsor Frontiers in Bioscience Research Institute and Aging, Irvine, CaliforniaEarly phase 1, single group, no placebo. 48 adults aged 50 or older (estimated) apply a serum of GHK-Cu, AHK-Cu, epitalon and two other small peptides to some skin areas, compared with untreated areas, alongside oral or injected drugs such as metformin. Main result: "biological age" from gene-activity clocks at 4 weeks.Enrolling by invitation. First posted October 22, 2026; estimated completion October 14, 2028.
NCT07706361, sponsor LifeWave, Inc.A skin patch (registered as a device), first open-label and then versus a placebo patch, worn daily for 7 days by 100 healthy adults (estimated). Main result: blood levels of GHK and GHK-Cu at day 8.Not yet recruiting. Estimated start January 2027.

None of these trials injects GHK-Cu. The CuHeal design is the strongest: each person is their own control, and the people judging the wounds do not know which gel went where. Its main results are not expected before February 2027.

Human evidence so far

Human evidence. It is small and almost all topical.

  • In a 1992 randomized trial in 86 people with venous leg ulcers, a tripeptide-copper complex cream did no better than an inactive cream; silver sulfadiazine cream shrank ulcers more than either. The abstract does not name the peptide.
  • In a 2006 randomized study of 13 people after CO2 laser skin resurfacing, GHK-Cu skin care made no measurable difference to redness, wrinkles or skin quality, though people using it reported higher satisfaction.
  • An August 2026 systematic review in Aesthetic Surgery Journal found 20 studies on GHK-Cu in aesthetics, 18 of them preclinical and 2 randomized trials, and called for "larger, controlled trials".
  • On November 4, 2026, the same journal published a letter titled "Mechanistic Plausibility Should not be Conflated With Clinical Validation" of GHK-Cu, and the review authors replied on November 10. That debate is the honest state of play.
  • A November 2026 systematic review of peptides for hair loss gave a grade B recommendation to formulas containing glycyl-histidyl-lysine peptide. It highlights combinations of several peptides, so the effect of GHK on its own is unclear.

We found no published controlled trial of injected GHK-Cu in people.

Animal and lab evidence

Animal evidence. In a 2003 rat study, a GHK-Cu gel sped the healing of wounds with poor blood supply compared with an inactive gel and no treatment. In a 2015 rat study, GHK-Cu injected into the knee improved graft healing after ACL reconstruction at 6 weeks, but the benefit was gone by 12 weeks.

Lab evidence. Cell studies report effects on collagen and inflammation signals, summarized in the 2026 review. Cell results show a possible mechanism, not a benefit in people.

Where FDA stands

  • FDA's list of compounding substances that may present significant safety risks includes GHK-Cu for injectable routes, with this note: possible risk of immune reactions "due to the potential for aggregation and peptide-related impurities", and "limited data in humans".
  • FDA's 503A category list, updated May 14, 2026, puts GHK-Cu (except for injectable routes) back in category 1, under evaluation, after one nominator kept its nomination for non-injectable routes. FDA says it intends to consult its compounding advisory committee about GHK-Cu before the end of February 2027.
  • GHK-Cu is not one of the six peptides in the October 2026 HHS draft policy. See our HHS policy breakdown.

What this means for you

A copper peptide cream and a GHK-Cu injection are different things with different evidence. The skin studies are small and mixed, and the injected form has no published human trials. If you are thinking about GHK-Cu, talk to your clinician first and treat any dose you read about as research information, not a plan. Watch for two dates: FDA's advisory committee review, planned before the end of February 2027, and the CuHeal wound trial's estimated primary completion in February 2027.


Frequently asked questions

Has GHK-Cu been tested in humans?+
Yes, but mostly as a cream or serum on the skin, in small studies. As of November 15, 2026, we found no published controlled trial of injected GHK-Cu in people.
What GHK-Cu trials were registered in 2026?+
NCT07437586, a phase 2 trial of a GHK-Cu gel on small skin wounds in 60 healthy adults (recruiting since February 2, 2026), and NCT07888595, a single-group aging study using a serum of GHK-Cu and other peptides (posted October 22, 2026). A blood-level study of a skin patch, NCT07706361, was posted in July 2026.
Is GHK-Cu FDA approved?+
No. GHK-Cu is used in cosmetics, but it is not approved as a drug. FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks.
What is FDA doing about GHK-Cu?+
On May 14, 2026, FDA put GHK-Cu for non-injectable routes back into category 1, under evaluation, and said it intends to consult its Pharmacy Compounding Advisory Committee about it before the end of February 2027.
Is GHK-Cu in the HHS six-peptide policy?+
No. The October 2026 HHS draft policy covers BPC-157, TB-500, MOTS-c, KPV, semax and epitalon, not GHK-Cu.

Sources

Every fact in this article comes from one of these sources, checked on November 15, 2026. Injected GHK-Cu is a research peptide, not approved for human use. This article is for education. It is not medical advice, and nothing here is a dose recommendation.

  1. ClinicalTrials.gov. NCT07437586: Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal). First posted February 27, 2026. clinicaltrials.gov
  2. ClinicalTrials.gov. NCT07888595: Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. First posted October 22, 2026. clinicaltrials.gov
  3. ClinicalTrials.gov. NCT07706361: Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults. First posted July 15, 2026. clinicaltrials.gov
  4. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026. fda.gov/media/94155/download
  5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. fda.gov
  6. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID 18644225. PubMed
  7. Bishop JB, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150. PubMed
  8. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171. PubMed
  9. Mokhtar J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. 2026. PMID 42619529. PubMed
  10. Rahman E, Webb WR. Mechanistic plausibility should not be conflated with clinical validation of glycyl-L-histidyl-L-lysine-copper. Aesthet Surg J. November 4, 2026. PMID 42981269. PubMed
  11. Mokhtar J, Lellouch AG. Response to: Mechanistic plausibility should not be conflated with clinical validation of GHK-Cu. Aesthet Surg J. November 10, 2026. PMID 43006658. PubMed
  12. Joerg L, et al. Peptides for hair growth and treatment of hair loss and alopecia: a systematic review. J Drugs Dermatol. November 2026. PMID 42976838. PubMed
  13. Canapp SO Jr, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003. PMID 14648529. PubMed
  14. Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PMID 25731775. PubMed